Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shubham Pant

Showing results (141-150 of 181) with videos related to

Pageof 19
Sort By:
The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 20, 2025
Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic SignificanceYan Zhu, Luisa Maren Solis Soto, Shubham Pant, et al.
Cancer Discovery|July 18, 2022
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic CancerAislyn Schalck, Donastas Sakellariou-Thompson, Marie-Andrée Forget, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe Amaria, Anne Knisely, David Vining, et al.
The Lancet. Oncology|September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trialAung Naing, Deborah J Wong, Jeffrey R Infante, et al.
British Journal of Cancer|April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancersShiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJi Son, Heather Y Lin, Siqing Fu, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaAnne M Noonan, Matthew R Farren, Susan M Geyer, et al.
The Lancet. Oncology|November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion studyFunda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
Pageof 19

Showing results (141-150 of 181) with videos related to

Sort By:
Pageof 19
The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 20, 2025
Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic SignificanceYan Zhu, Luisa Maren Solis Soto, Shubham Pant, et al.
Cancer Discovery|July 18, 2022
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic CancerAislyn Schalck, Donastas Sakellariou-Thompson, Marie-Andrée Forget, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe Amaria, Anne Knisely, David Vining, et al.
The Lancet. Oncology|September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trialAung Naing, Deborah J Wong, Jeffrey R Infante, et al.
British Journal of Cancer|April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancersShiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJi Son, Heather Y Lin, Siqing Fu, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaAnne M Noonan, Matthew R Farren, Susan M Geyer, et al.
The Lancet. Oncology|November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion studyFunda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
Pageof 19